Reports Q4 revenue $37.61M, consensus $37.73M. “2023 was another strong year for OrthoPediatrics as we delivered record top-line results and outperformed our adjusted EBITDA expectations. We continue to benefit from an extremely diverse business from which we saw strength across all segments this year. Both our trauma and deformity and scoliosis businesses continue to capture market share and drive growth,” commented David Bailey, President & CEO of OrthoPediatrics. “Looking ahead, we believe we are in an extremely strong position for 2024 and we have the right drivers in place to sustain our strong revenue and profitability growth. We look forward to helping the next million kids with our portfolio of the most advanced pediatric orthopedic solutions.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results
- OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis
- KIDS Earnings this Week: How Will it Perform?
- OrthoPediatrics participates in a conference call with BTIG
- OrthoPediatrics Corp. Named One of the 2024 Best Places to Work in Indiana